Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

Y-MABS THERAPEUTICS, INC.

(YMAB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Y-Mabs Therapeutics, Inc. Announces Priority Review of BLA for DANYELZA« (Naxitamab-Gqgk) in China

09/13/2021 | 09:00am EDT

Y-mAbs Therapeutics, Inc. announced that its partner SciClone Pharmaceuticals Limited has been granted priority review of the Biologics License Application (“BLA”) for DANYELZA for the treatment of patients with relapsed/refractory high-risk neuroblastoma by the Center for Drug Evaluation (“CDE”) of China’s National Medical Products Administration (“NMPA”).


ę S&P Capital IQ 2021
All news about Y-MABS THERAPEUTICS, INC.
10/08Y MABS THERAPEUTICS : mAbs 177Lu-omburtamab-DTPA for the Treatment of Patients with Medull..
AQ
10/07Y MABS THERAPEUTICS : Gets FDA's Rare Pediatric Disease Designation for Potential Therapy ..
MT
10/07Y MABS THERAPEUTICS : mAbs' 177Lu-omburtamab-DTPA for the Treatment of Patients with Medul..
PU
10/07Y-MABS THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
10/07Y MABS THERAPEUTICS : mAbs' 177Lu-omburtamab-DTPA for the Treatment of Patients with Medul..
AQ
10/07U.S. Food and Drug Administration Grants Rare Pediatric Disease Designation for Y-mAbs’..
CI
10/04INSIDER SELL : Y-mabs Therapeutics
MT
09/23INSIDER SELL : Y-mabs Therapeutics
MT
09/16Y MABS THERAPEUTICS : mAbs Announces Data to be Presented at SIOP 2021
AQ
09/14Y MABS THERAPEUTICS : mAbs Announces Priorit Review of BLA for DANELZA (naxitamab-gqgk) in..
AQ
More news
Analyst Recommendations on Y-MABS THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 71,5 M - -
Net income 2021 -42,6 M - -
Net cash 2021 83,9 M - -
P/E ratio 2021 -31,0x
Yield 2021 -
Capitalization 1 163 M 1 163 M -
EV / Sales 2021 15,1x
EV / Sales 2022 6,79x
Nbr of Employees 125
Free-Float 83,7%
Chart Y-MABS THERAPEUTICS, INC.
Duration : Period :
Y-mAbs Therapeutics, Inc. Technical Analysis Chart | YMAB | US9842411095 | MarketScreener
Technical analysis trends Y-MABS THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 26,68 $
Average target price 55,33 $
Spread / Average Target 107%
EPS Revisions
Managers and Directors
Claus Juan M°ller-San Pedro Chief Executive Officer & Director
Thomas Gad Chairman, President & Head-Business Development
Bo Kruse CFO, Secretary. Treasurer & Executive VP
Torben Lund-Hansen Chief Technology Officer & Senior Vice President
Steen Lisby Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
Y-MABS THERAPEUTICS, INC.-46.11%1 163
GILEAD SCIENCES, INC.16.08%84 795
WUXI APPTEC CO., LTD.29.45%66 184
BIONTECH SE203.83%59 820
REGENERON PHARMACEUTICALS14.52%57 519
VERTEX PHARMACEUTICALS-23.09%47 156